ACR CONVERGENCE
DO NOT MISS

Oral Presentations and Posters
Networking event
Educational events
Dear young rheumatologists and researchers in rheumatology,

We are happy to present you a new issue of EMEUNEWS with a selection of not to be missed abstracts at this year’s ACR virtual annual meeting.

In this newsletter, we provide you with a selection of oral presentations and posters, thoughtfully picked by our contributors, that we consider being noteworthy. The selection is personal and limited and cannot capture all of the exciting new research to be presented. However, we hope it provides an overview of some interesting sessions.

In addition, this Newsletter contains details about EMEUNET events organized during the Congress.

EMEUNET is active on social media channels, such as Facebook, Twitter and LinkedIn, in addition to our website and the dynamic presence in all major rheumatology events.

If this is your first contact with EMEUNET, we invite you to explore more, and join us. If you are already part of our community, we kindly remind you that sharing is caring. Spread the word about our activities and work and help us reach more young rheumatologists and researchers.

We hope you enjoy reading this Newsletter. We always welcome feedback, comments, suggestions, and contributions.

We wish you a prolific and successful ACR Convergence 2021. Stay safe, and see you online!

Tadeja Kuret, Diego Benavent and Mikhail Protopopov on behalf of the Newsletter Sub-Committee
Daniele attained his PhD at Centre for Experimental Medicine and Rheumatology at the Queen Mary University of London (UK) and now is a rheumatologist in training the University of Campania “L. Vanvitelli” in Naples (IT). His research is now mainly focused on Spondyloarthritis and mucosal immunology. He previously worked on the involvement of ubiquitination pathways in the pathogenesis of autoimmune rheumatic diseases. Daniele is member of the Visibility and Global Affairs Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Spondyloarthritis Including PsA – Basic Science Poster</td>
<td>Groen, S (Denmark)</td>
<td>DEVELOPMENT OF A NOVEL CARTILAGE MODEL CO-CULTURED WITH CONDITIONED MEDIUM FROM TH17 CELLS TO EXPLORE THE EFFECT OF IL-17A ON JOINT TISSUE REMODELLING</td>
</tr>
<tr>
<td>Poster</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Spondyloarthritis Including PsA – Basic Science Poster</td>
<td>Harvey, N (UK)</td>
<td>MENDELIAN RANDOMISATION ANALYSIS OF PROTEIN QUANTITATIVE TRAIT LOCI WITH ANKYLOSING SPONDYLITIS REVEALS CAUSATIVE INVOLVEMENT OF KEY EFFECTOR PROTEINS AND PATHWAYS</td>
</tr>
<tr>
<td>Oral</td>
<td>Saturday 06.11.2021 10:30</td>
<td>RA – Etiology &amp; Pathogenesis</td>
<td>Mueller, A (UK)</td>
<td>SINGLE CELL PROFILING REVEALS A WNT-MEDIATED TRANSCRIPTIONAL GRADIENT THAT DRIVES INFLAMMATION IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST PATHOLOGY</td>
</tr>
<tr>
<td>Oral</td>
<td>Saturday 06.11.2021 11:00</td>
<td>SLE – Animal Models</td>
<td>Dudhgaonkar, S (India)</td>
<td>INHIBITION OF TOLL-LIKE RECEPTOR 7 (TLR7) WITH THE POTENT AND SELECTIVE INHIBITOR OF HUMAN TLR7 AND TLR8 BMS-986256 PROVIDES ROBUST EFFICACY IN MURINE LUPUS MODELS, REVERSING ESTABLISHED DISEASE</td>
</tr>
<tr>
<td>Oral</td>
<td>Tuesday 09.11.2021 09:45</td>
<td>RA – Animal Models</td>
<td>Trent, B (USA)</td>
<td>PROMOTION OF AUTOIMMUNE ARTHRITIS VIA TRYPTOPHAN METABOLISM AND PRODUCTION OF THE BACTERIAL-DERIVED TRYPTOPHAN METABOLITE INDOLE</td>
</tr>
<tr>
<td>Oral</td>
<td>Saturday 07.11.2021 17:00</td>
<td>Genetics, Genomics &amp; Proteomics</td>
<td>Shaw, T (USA)</td>
<td>SKewed ESCAPE FROM X-INACTIVATION: INSIGHTS INTO THE FEMALE BIAS OF SJögren’S SYNDROME</td>
</tr>
</tbody>
</table>

A novel in vitro model for studying the contribution of IL-17 producing cells on bone and cartilage damage in SpA.

One of the rare protein Quantitative Trait Loci (pQTL) studies investigating the functional role of SNPs in SpA.

The study provides novel insights into the role of WNT signalling in synovial inflammation.

The study identified TLR7 as a novel therapeutic target in SLE.

Further evidence of the contribution of intestinal microbiota to arthritis onset.

Genetic explanation for the sex bias in Sjögren’s syndrome.
Tadeja Kuret

Tadeja is a postdoctoral research associate at Institute of Cell Biology, Faculty of Medicine, University of Ljubljana in Slovenia. Her major research interests include primary systemic vasculitis (giant cell arteritis and IgA vasculitis), chronic inflammation, biomarker discovery, single cell RNA sequencing and systems biology. Tadeja is a member of the EMEUNET Newsletter Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 0440</td>
<td>Saturday 06.11.2021 09:45</td>
<td>Immunological Complications of Therapy</td>
<td>Mathias, K (USA)</td>
<td>ASSOCIATION BETWEEN RHEUMATIC AUTOANTIBODY POSITIVITY AND IMMUNE-RELATED ADVERSE EVENTS</td>
</tr>
<tr>
<td>Oral 0472</td>
<td>Saturday 06.11.2021 11:30</td>
<td>SLE – Animal Models (0470–0473)</td>
<td>Hoover, P (USA)</td>
<td>AN ATLAS OF HUMAN AND MOUSE INTRARENAL IMMUNE CELLS IN LUPUS NEPHRITIS REVEALS HOMOLOGOUS IMMUNE POPULATIONS ACROSS COMMON MOUSE STRAINS AND SPECIES</td>
</tr>
<tr>
<td>Oral 0966</td>
<td>Sunday 07.11.2021 10:30</td>
<td>T Cell Biology &amp; Targets in Autoimmune &amp; Inflammatory Disease</td>
<td>Dunlap, G (USA)</td>
<td>INTEGRATED SINGLE CELL RNA-SEQUENCING ANALYSIS OF TISSUE-LOCALIZED T CELLS IN CUTANEOUS LUPUS AND LUPUS NEPHRITIS</td>
</tr>
<tr>
<td>Oral 0969</td>
<td>Sunday 07.11.2021 11:15</td>
<td>T Cell Biology &amp; Targets in Autoimmune &amp; Inflammatory Disease</td>
<td>Floudas, A (Ireland)</td>
<td>LOSS OF BALANCE BETWEEN PROTECTIVE AND PRO-INFLAMMATORY SYNOVIAL TISSUE T CELL POLYFUNCTIONALITY PREDATES CLINICAL ONSET OF RHEUMATOID ARTHRITIS</td>
</tr>
<tr>
<td>Poster 1001</td>
<td>Monday 08.11.2021 08:30</td>
<td>Innate Immunity Poster</td>
<td>Pioi, P (USA)</td>
<td>EXOSOMES MEDIATE A COOPERATIVE MECHANISM OF MACROPHAGE/FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS</td>
</tr>
<tr>
<td>Oral 1936</td>
<td>Tuesday 09.11.2021 16:15</td>
<td>Genetics, Genomics &amp; Proteomics</td>
<td>Fava, A (USA)</td>
<td>A NEUTROPHIL DEGRANULATION SIGNATURE IDENTIFIES PROLIFERATIVE LUPUS NEPHRITIS</td>
</tr>
</tbody>
</table>

Use of novel, non invasive fluorescent lifetime imaging microscopy (FLIM).

The first study showing that human SSc dermal fibroblasts can mediate macrophage activation through exosomes.

Neutrophil activity could be non-invasively monitored to assist with the diagnosis of proliferative lupus nephritis.
Mrinalini is an academic rheumatology trainee in Liverpool, UK. She has a research interest in epidemiology, comorbidities and infection in rheumatic diseases. She is a member of the Social Media Sub-Committee and part of the EMEUNET podcast production team.

### RHEUMATOID ARTHRITIS I – Non therapeutic

Mrinalini Dey

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0288</td>
<td>Saturday 06.11.2021 08:30</td>
<td>RA – Diagnosis, Manifestations, &amp; Outcomes</td>
<td>McDermott, G (USA)</td>
<td>DEMOGRAPHIC, LIFESTYLE, AND CLINICAL RISK FACTORS FOR RHEUMATOID ARTHRITIS-ASSOCIATED BRONCHIECTASIS: ROLE OF RA-RELATED AUTOANTIBODIES</td>
</tr>
<tr>
<td>Oral 0455</td>
<td>Saturday 06.11.2021 11:15</td>
<td>Plenary I</td>
<td>Rech, J (Germany)</td>
<td>ABATACEPT REVERSES SUBCLINICAL ARTHRITIS IN PATIENTS WITH HIGH-RISK TO DEVELOP RHEUMATOID ARTHRITIS - RESULTS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIA STUDY IN RA-AT RISK PATIENTS</td>
</tr>
<tr>
<td>Poster 0797</td>
<td>Sunday 07.11.2021 08:30</td>
<td>RA – Diagnosis, Manifestations, &amp; Outcomes</td>
<td>Doumen, M (Belgium)</td>
<td>PSYCHOSOCIAL WELLBEING AND ILLNESS PERCEPTIONS DURING THE EARLY DISEASE PHASE PREDICT SUSTAINED REMISSION IN RHEUMATOID ARTHRITIS</td>
</tr>
</tbody>
</table>

Multi-centre study of abatacept use in patients at risk of rheumatoid arthritis (RA).

Study exploring the association between psychosocial wellbeing and sustained remission in early RA, with implications for unmet needs in this area and person-centred interventions.

| Oral 0958 | Sunday 07.11.2021 11:00 | Plenary II | Charles-Schoeman, C (USA) | RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RA AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3B/4 RANDOMIZED SAFETY STUDY OF TOFACITINIB VS TNF INHIBITORS |
| Oral 1448 | Monday 08.11.2021 14:30 | Abstracts: Clinical Epidemiology | Solomon, DH (USA) | VIRTUAL VISITS VERSUS FACE-TO-FACE VISITS FOR RHEUMATOID ARTHRITIS (RA): COMPARISON OF TREAT TO TARGET (TTT) ADHERENCE IN 18 US RHEUMATOLOGY PRACTICES |

Cardiovascular safety profile in tofacitinib compared with TNF inhibitors in patients with RA.

Implementation of treat-to-target during COVID pandemic, comparing face-to-face and virtual appointments.

<table>
<thead>
<tr>
<th>Poster 1661</th>
<th>Tuesday 09.11.2021 08:30</th>
<th>RA – Diagnosis, Manifestations, &amp; Outcomes</th>
<th>Schieir, O (Canada)</th>
<th>SEX-STRATIFIED PATTERNS OF MULTIMORBIDITY AT RA ONSET AND ASSOCIATED LONGITUDINAL IMPACTS ON DISABILITY OVER THE FIRST YEAR FOLLOW UP: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT</th>
</tr>
</thead>
</table>

Multimorbidity at RA onset and its implications.
Stefan is a rheumatology specialist and lecturer at the University of Medicine and Pharmacy Craiova (Romania). His main research interests include rheumatoid arthritis, musculoskeletal ultrasound and SLE. Stefan is a member of the Social Media Subcommittee.

### Real-world outcomes of different medication tapering for RA in sustained remission.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0819</td>
<td>Sunday 07.11.2021 8:30</td>
<td>RA – Treatments Poster I</td>
<td>Tageldin, M (USA)</td>
<td>A REAL-WORLD 2-YEAR PROSPECTIVE STUDY OF MEDICATION TAPERING IN PATIENTS WITH RA IN SUSTAINED REMISSION IN THE RHEUMATOID ARTHRITIS MEDICATION TAPERING (RHEUMTAP) COHORT</td>
</tr>
<tr>
<td>Poster 0844</td>
<td>Sunday 07.11.2021 8:30</td>
<td>RA – Treatments Poster I</td>
<td>Keeling, S (Canada)</td>
<td>SWITCHING BILOGICS AND FAILURE TO ATTAIN REMISSION IN THE FIRST YEAR PREDICTS bDMARD REFRACTORY DISEASE IN RHEUMATOID ARTHRITIS: A 15-YEAR FOLLOW UP OF THE ALBERTA BIOLOGICS PHARMACOVIGILANCE COHORT</td>
</tr>
</tbody>
</table>

### Failure to obtain disease remission within the first year can predict long-term RA outcomes.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 1251</td>
<td>Monday 08.11.2021 8:30</td>
<td>RA – Treatments Poster II</td>
<td>Hernández-Breijo, B (Spain)</td>
<td>SERUM B CELL ACTIVATING FACTOR REFLECTS GOOD EULAR RESPONSE TO TNF INHIBITION IN PATIENTS WITH RHEUMATOID ARTHRITIS</td>
</tr>
</tbody>
</table>

### Levels of serum BAFF can predict TNFi response at 6 month in ACPA positive patients.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 1255</td>
<td>Monday 08.11.2021 8:30</td>
<td>RA – Treatments Poster II</td>
<td>Cohen, S (USA)</td>
<td>A MOLECULAR SIGNATURE RESPONSE CLASSIFIER PREDICTS THE LIKELIHOOD OF NON-RESPONSE TO TNF INHIBITOR THERAPIES IN RA AT 3 MONTHS</td>
</tr>
</tbody>
</table>

### Baseline molecular signature profile could guide the first choice of biologic in RA.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 1442</td>
<td>Monday 08.11.2021 14:00</td>
<td>RA – Treatments II: New Findings in Established Therapies</td>
<td>Pombo-Suárez, M (Spain)</td>
<td>EFFECTIVENESS OF CYCLING JAKI COMPARED TO SWITCHING TO bDMARD IN PATIENTS WHO FAILED A FIRST JAKI IN AN INTERNATIONAL COLLABORATION OF REGISTRIES OF RHEUMATOID ARTHRITIS PATIENTS (THE JAK-POT STUDY)</td>
</tr>
</tbody>
</table>

### Cycling JAKi showed similar effectiveness and drug survival rates to bDMARD switching, after failure of first JAKi.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 1684</td>
<td>Tuesday 09.11.2021 8:30</td>
<td>RA – Treatments Poster III</td>
<td>Bălănescu, A (Romania)</td>
<td>INCIDENCE OF INFECTIONS IN PATIENTS AGED ≥ 50 YEARS WITH RA AND ≥ 1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3B/4 RANDOMIZED SAFETY STUDY OF TOFACITINIB VS TNF INHIBITORS</td>
</tr>
</tbody>
</table>

Higher overall infections in RA patients ≥ 50 years with ≥ 1 additional CV risk factor treated with Tofacitinib vs TNFi.
Gizem is a first-year rheumatology fellow at Hacettepe University Medical Faculty in Ankara. She has recently joined to Young-GRAPPA team and will work as the education leader. Her major research interests are inflammatory arthritis particularly psoriatic arthritis and outcome measures in rheumatic diseases. Gizem is a member of the Newsletter Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0363</td>
<td>Saturday 06.11.2021 09:00</td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes Poster I</td>
<td>Poddubnyy, D (Germany)</td>
<td>DISEASE COURSE AND DISEASE BURDEN IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM 5-YEAR MULTICOUNTRY PROSPECTIVE OBSERVATIONAL STUDY</td>
</tr>
<tr>
<td>Included patients from 29 countries with nr-axSpA (n=562) and r-axSpA (n=1050) over 5 years of follow-up.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster 0374</td>
<td>Saturday 06.11.2021 09:30</td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes Poster I</td>
<td>Proft, F (Germany)</td>
<td>VALIDATION OF THE AxSPA DISEASE ACTIVITY SCORE WITH A QUICK QUANTITATIVE CRP ASSAY (ASDAS-qCRP) IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A PROSPECTIVE, NATIONAL, MULTICENTER STUDY</td>
</tr>
<tr>
<td>The ASDAS-qCRP has an important time advantage which can be integrated in clinical routine and clinical trials in the future.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral 0450</td>
<td>Saturday 06.11.2021 09:45</td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes Poster I</td>
<td>Hwang, M (USA)</td>
<td>IDENTIFYING TRAJECTORIES OF RADIOGRAPHIC SPINAL DISEASE IN ANKYLOSING SPONDYLITIS</td>
</tr>
<tr>
<td>Identified four major spinal progression patterns of spinal disease.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster 0904</td>
<td>Sunday 07.11.2021 09:00</td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes Poster II</td>
<td>Maksymowych, W (Canada)</td>
<td>DATA-DRIVEN DEFINITIONS BASED ON INFLAMMATORY LESIONS FOR A POSITIVE MRI OF THE SPINE CONSISTENT WITH AXIAL SPONDYLOARTHRITIS</td>
</tr>
<tr>
<td>Show end primary candidate quantitative cut-offs based on numbers of vertebral corners that define a positive MRI for axSpA.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster 1789</td>
<td>Tuesday 09.11.2021 09:30</td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes Poster IV</td>
<td>Cruz Correa, O (USA)</td>
<td>PREDICTION OF PSORIATIC ARTHRITIS IN PATIENTS WITH PSORIASIS USING DNA METHYLATION PROFILES</td>
</tr>
<tr>
<td>36 highly significant methylation markers can predict the development of PsA at an early stage.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral 1922</td>
<td>Tuesday 09.11.2021 14:45</td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes II</td>
<td>Sengupta, R (UK)</td>
<td>EARLY AND ACCURATE DIAGNOSIS OF PATIENT WITH AxSpA USING MACHINE LEARNING: A PREDICTIVE ANALYSIS FROM ELECTRONIC HEALTH RECORDS IN UNITED KINGDOM</td>
</tr>
<tr>
<td>Machine learning algorithm demonstrated a high level of accuracy and precision in the identification of axSpA candidates.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Xabier is a Rheumatology and Emergency Medicine consultant at Vall d’Hebron University Hospital, Barcelona, Spain. He also holds a visiting research fellow position at the Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, UK. His main research interests are in the field of SpA and he is the current leader of the Country Liaison Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0364</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes Poster I</td>
<td>Wetterslev, M (Denmark)</td>
<td>DOSE TAPERING OF TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHITIS IN ROUTINE CARE – 2-YEAR CLINICAL AND MRI OUTCOMES AND PREDICTORS OF SUCCESSFUL TAPERING</td>
</tr>
</tbody>
</table>

Dose tapering study with meaningful results for clinical practice.

| Oral 0453 | Saturday 06.11.2021 10:45 | Plenary Session I | Ostor, A (Australia) | EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: 24-WEEK INTEGRATED RESULTS FROM 2 PHASE 3, RANDOMIZED, DOUBLE-BLIND CLINICAL TRIALS FOR CSDMARD-IR AND BIO-IR PATIENTS |

Efficacy results of a new IL-23 inhibitor in both naïve and bDMARDs exposed PsA patients with a strong safety profile.

| Poster 0922 | Sunday 07.11.2021 08:30 | Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis | Deodhar, A (USA) | BIMEKIZUMAB SHOWS SUSTAINED AND MEANINGFUL LONG-TERM IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN ANKYLOSING SPONDYLITIS: INTERIM RESULTS AFTER 3 YEARS OF TREATMENT IN AN ONGOING PHASE 2B STUDY |

Bimekizumab shows sustained long-term improvements in quality of life.

| Poster 0924 | Sunday 07.11.2021 08:30 | Spondyloarthritis Including PsA – Treatment Poster I: Axial Spondyloarthritis | van der Heijde, D (Netherlands) | EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION |

Long term sustained and consistent efficacy of a JAK inhibitor (Upadacitinib) in ankylosing spondylitis.

| Poster 1309 | Monday 08.11.2021 08:30 | Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III | Puche- Larrubia, M (Spain) | IMPACT OF THE NUMBER OF COMORBIDITIES ON THE OUTCOME MEASURES AND ON THE RETENTION RATE OF THE FIRST ANTI-TNF IN PATIENTS WITH ANKYLOSING SPONDYLITIS: TWO-YEAR FOLLOW-UP REGISRESPON-AS |

Study looking at comorbidity impact in the survival of first TNF inhibitor in ankylosing spondylitis.

| Poster 1330 | Monday 08.11.2021 08:30 | Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I | Mease, P (USA) | EFFECT OF GUSELKUMAB (TREMFYA®), A SELECTIVE IL-23P19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS |

Relevant data on axial involvement in PsA treated with IL-23p19 inhibitor.
Emre is a rheumatologist at Hacettepe University (Ankara, Türkiye) and a MSc candidate in Epidemiology. Emre is a member of the Social Media Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0071</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Antiphospholipid Syndrome</td>
<td>Balbi, G (Brazil)</td>
<td>DAMAGE ACCRUAL MEASURED BY DIAPS IN ANTIPHOSPHOLIPID ANTIBODY (APl)-POSITIVE PATIENTS: RESULTS FROM ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS AND INTERNATIONAL NETWORKING (APS ACTION) CLINICAL DATABASE AND REPOSITORY (“REGISTRY”)</td>
</tr>
<tr>
<td>Poster 0866</td>
<td>Sunday 07.11.2021 08:30</td>
<td>SLE – Diagnosis, Manifestations, &amp; Outcomes Poster II: Manifestations (0855–0896)</td>
<td>Ugarte-Gil, M (Peru)</td>
<td>CHARACTERISTICS ASSOCIATED WITH POOR COVID-19 OUTCOMES IN PEOPLE WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): DATA FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (GRA)</td>
</tr>
<tr>
<td>Poster 0885</td>
<td>Sunday 07.11.2021 08:30</td>
<td>SLE – Diagnosis, Manifestations, &amp; Outcomes II: Manifestations</td>
<td>Barraclough, M (UK)</td>
<td>SLE PHENOTYPES FORMED FROM MACHINE LEARNING AND THEIR ASSOCIATIONS WITH COGNITIVE IMPAIRMENT</td>
</tr>
<tr>
<td>Oral 1420</td>
<td>Monday 08.11.2021 09:00</td>
<td>SLE – Diagnosis, Manifestations, &amp; Outcomes I: COVID-19 Vaccine Experience &amp; Translational Science (1420–1423)</td>
<td>Izmirly, P (USA)</td>
<td>EVALUATION OF SARS-COV-2 VACCINE RESPONSE IN A MULTI-RACIAL/ETHNIC COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS</td>
</tr>
<tr>
<td>Oral 1458</td>
<td>Monday 08.11.2021 15:30</td>
<td>SLE – Treatment: New Agents, Old Agents (1458–1463)</td>
<td>Merrill, J (USA)</td>
<td>SUSTAINED EFFICACY AND SAFETY OF IBERDOMIDE TO WEEK 52 IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY</td>
</tr>
</tbody>
</table>

Damage accrual measured by DIAPS in aPl-positive patients was assessed in a large international cohort.

BT-104 which functions through increasing the suppressive capacity and stability of regulatory CD4+ T cells, supporting the metabolic demands of autophagy in phagocytes showed promising evidence for SLE.

One of the largest cohorts reporting the COVID-19 course in SLE patients.

Artificial intelligence-based approach to cognitive impairment might lead to more personalized SLE treatment.

This study has a strong methodological power for assessing the COVID-19 vaccine response in SLE patients.

Iberdomide, that promotes proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), was associated with sustained clinical benefit.
Mikhail Protopopov

Mikhail is a rheumatologist and a junior researcher at the Department of Gastroenterology, Infectiology and Rheumatology, Charité University, Berlin, Germany. His major research interests include spondyloarthritis and psoriatic arthritis (clinical aspects, imaging, epidemiology and outcomes). Mikhail is the Leader of the Newsletter Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0210</td>
<td>Saturday 06.11.2021 08.30</td>
<td>Osteoarthritis – Clinical Poster I</td>
<td>Costello, K (USA)</td>
<td>USING MACHINE LEARNING TO PREDICT MEDIAL KNEE CARTILAGE WORSENING OVER 2 YEARS USING GAIT AND PHYSICAL ACTIVITY: THE MOST STUDY</td>
</tr>
<tr>
<td>Poster 0217</td>
<td>Saturday 06.11.2021 08.30</td>
<td>Osteoarthritis – Clinical Poster I</td>
<td>Maksymowycz, W (Canada)</td>
<td>THE OMERACT KNEE INFLAMMATION MRI SCORING SYSTEM: VALIDATION OF QUANTITATIVE METHODOLOGIES AND TRICOMPARTIMENTAL OVERLAYS BY COMPARISON WITH THE MRI OSTEOPOROSIS KNEE SCORE</td>
</tr>
<tr>
<td>Oral 0445</td>
<td>Saturday 06.11.2021 09.30</td>
<td>Osteoporosis &amp; Metabolic Bone Disease – Basic &amp; Clinical Science</td>
<td>Adachi, J (Canada)</td>
<td>SAFETY AND EFFICACY OF DENOSUMAB VS RISEDRONATE IN PATIENTS WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND RHEUMATOID ARTHRITIS</td>
</tr>
<tr>
<td>Poster 0729</td>
<td>Sunday, 07.11.2021 08.30</td>
<td>Osteoarthritis – Clinical Poster II</td>
<td>Simsek, I (USA)</td>
<td>A MULTICENTER, OBSERVATIONAL, EXTENSION STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF A SINGLE LORECIVIVINT INJECTION IN KNEE OA SUBJECTS</td>
</tr>
<tr>
<td>Poster 0733</td>
<td>Sunday, 07.11.2021 08.30</td>
<td>Osteoarthritis – Clinical Poster II</td>
<td>Maheu, E (France)</td>
<td>A NEW WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICE (actiTENS®) IS MORE EFFICIENT AND BETTER TOLERATED THAN WEAK OPIOIDS IN THE TREATMENT OF KNEE OSTEOPOROSIS PAIN</td>
</tr>
<tr>
<td>Poster 1144</td>
<td>Monday 08.11.2021 08.30</td>
<td>Osteoporosis &amp; Metabolic Bone Disease – Basic &amp; Clinical Science Poster</td>
<td>Mok, CC (China)</td>
<td>UNDERESTIMATION OF THE FRACTURE RISK BY THE FRAX FORMULA IN CHRONIC GLUCOCORTICOID USERS: A 10-YEAR LONGITUDINAL VALIDATION STUDY</td>
</tr>
</tbody>
</table>

Machine learning approach showed good performance for predicting cartilage worsening in knee joints over two years.

Validation results of the novel OMERACT Knee Inflammation MRI Scoring System (KIMRISS) are presented.

Head-to-head comparison of denosumab vs. risendronate in a large study including 300 patients; patients on denosumab showed significantly larger gains in bone mineral density and less osteoporotic fractures.

Lorecivivint, a novel intra-articular CLK/DYRK inhibitor modulating Wnt and inflammatory pathways appeared safe and well tolerated, showing greater improvements in both pain and function compared to placebo.

A novel wearable device showed better pain reduction and tolerability as compared to weak opioids in knee osteoarthritis.

The study showing the fracture risk in patients with RMDs using glucocorticosteroids is triple as high as calculated by FRAX.
Juan Molina Collada

Juan is a consultant rheumatologist specialised in ultrasound at Gregorio Marañón University Hospital, Madrid, Spain, and the secretary of the Musculoskeletal Ultrasound Group of the Spanish Society of Rheumatology. His major research interests include the use of imaging in rheumatoid arthritis, spondyloarthritis and large vessel vasculitis. Juan is a member of the Education Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
</table>
| Poster   | Sunday, 07.11.2021
08:00     | Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I | Ruiz-Simón, S (Spain) | ACTIVE SCREENING FOR GOUT PERMITS IDENTIFYING A LARGER CARDIOVASCULAR POPULATION AT HIGH MORTALITY RISK |
| Poster   | Sunday, 07.11.2021
08:30     | Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I | Tiku, A (Australia)  | URATE-LOWERING THERAPY FOR PREVENTION OF GOUT: PRESPECIFIED ANALYSES FROM THE CKD-FIX TRIAL        |
| Poster   | Tuesday, 09.11.2021
08:30     | Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II | Flood, R (Ireland)   | HYPERURICEMIA IS ASSOCIATED WITH VASCULAR ENDOTHELIAL DYSFUNCTION – THE IMPACT OF HYPERURICEMIA ON FLOW MEDIATED AND NITROGLYCERIN MEDIATED DILATATION OF THE BRACHIAL ARTERY |
| Poster   | Tuesday, 09.11.2021
08:30     | Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II | Sirotti, S (Italy)   | CREATION OF AN ULTRASONOGRAPHIC SCORING SYSTEM FOR CPPD EXTENT: RESULTS FROM A DELPHI PROCESS BY THE OMERACT US WORKING GROUP |
| Oral     | Tuesday, 09.11.2021
10:30     | Metabolic & Crystal Arthropathies – Basic & Clinical Science          | Dalbeth, N (New Zealand) | A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL OF INTENSIVE SERUM URATE LOWERING WITH ORAL URATE-LOWERING THERAPY FOR EROSIve GOUT |
| Oral     | Tuesday, 09.11.2021
11:00     | Metabolic & Crystal Arthropathies – Basic & Clinical Science          | Helget, L (USA)       | MORTALITY IN PATIENTS WITH SUB-OPTIMALLY TREATED GOUT IN THE VETERAN'S HEALTH ADMINISTRATION: A NATIONAL RETROSPECTIVE COHORT STUDY |
| Oral     | Tuesday, 09.11.2021
11:15     | Metabolic & Crystal Arthropathies – Basic & Clinical Science          | O'Dell, J (USA)       | URATE LOWERING THERAPY IN THE TREATMENT OF GOUT: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF ALLOPURINOL AND FEBUXOSTAT USING A TREAT-TO-TARGET STRATEGY |

Gout was confirmed as an independent predictor of subsequent all-cause mortality in patients admitted for cardiovascular events

Allopurinol does not change the incidence of gout in people with chronic kidney disease at risk of progression

Hyperuricemia is associated with impaired vascular endothelial dysfunction

The first attempt to create a scoring system for Calcium Pyrophosphate crystals extent in patients affected by CPPD

Intensive serum urate lowering below 0.20mmol/L does not improve bone erosion scores in patients with erosive gout

Patients with gout receiving suboptimal gout management demonstrated higher rate of all-cause mortality.
Antigone Pieta

Antigone is a Rheumatology Fellow in the Rheumatology Clinic of University Hospital of Ioannina, Greece. Her research interest focuses on Systemic Lupus Erythematosus, response to treatment and disease activity metrics in systemic autoimmune diseases. She is also a member of Biomedical Research Foundation of the Academy of Athens, taking part in research projects regarding lupus. She is a member of the Country Liaison Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral 0952</td>
<td>Sunday 07.11.2021 09:00</td>
<td>Vasculitis – ANCA-Associated</td>
<td>Sattui, S (USA)</td>
<td>OUTCOMES OF COVID-19 INFECTION IN PATIENTS WITH PRIMARY SYSTEMIC VASCULITIS AND POLYMYALGIA RHEUMATICA: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN REGISTRY</td>
</tr>
<tr>
<td>Oral 0953</td>
<td>Sunday 07.11.2021 09:15</td>
<td>Vasculitis – ANCA-Associated</td>
<td>Quinn, K (USA)</td>
<td>AN INTERNATIONAL DELPHI EXERCISE TO IDENTIFY ITEMS OF IMPORTANCE FOR MEASURING RESPONSE TO TREATMENT FOR ANCA-ASSOCIATED VASCULITIS</td>
</tr>
<tr>
<td>Poster 1374</td>
<td>Monday 08.11.2021 08:30</td>
<td>Systemic Sclerosis &amp; Related Disorders – Clinical Poster II</td>
<td>Yuan, Y (USA)</td>
<td>A DEEP NEURAL NETWORK CLASSIFIER TO IDENTIFY INFLAMMATORY SYSTEMIC SCLEROSIS PATIENTS FROM HISTOLOGICAL IMAGES</td>
</tr>
<tr>
<td>Oral 1434</td>
<td>Monday 08.11.2021 10:30</td>
<td>Systemic Sclerosis &amp; Related Disorders – Basic Science</td>
<td>Farutin, V (USA)</td>
<td>MULTIOMIC STUDY OF SKIN, PERIPHERAL BLOOD AND SERUM: IS SERUM PROTEOME A REFLECTION OF DISEASE PROCESS AT THE END-ORGAN LEVEL IN SYSTEMIC SCLEROSIS?</td>
</tr>
<tr>
<td>Oral 1436</td>
<td>Monday 08.11.2021 11:00</td>
<td>Systemic Sclerosis &amp; Related Disorders – Basic Science</td>
<td>Elahee, M (USA)</td>
<td>EXPANDED PD-1hi CXCR5- HLA-DR+ T CELLS IS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS</td>
</tr>
<tr>
<td>Poster 1858</td>
<td>Tuesday 09.11.2021 08:30</td>
<td>Systemic Sclerosis &amp; Related Disorders – Clinical Poster III</td>
<td>Hinchcliff, M (USA)</td>
<td>SERUM INTERFERON SCORE IS A BIOMARKER OF ACTIVE DISEASE IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS ENROLLED IN THE PROSPECTIVE REGISTRY OF EARLY SYSTEMIC SCLEROSIS (PRESS) COHORT</td>
</tr>
</tbody>
</table>

**A large multinational registry investigating factors associated with COVID-19 outcomes in patients with PSV and PMR.**

**No formal criteria exist to measure treatment response in AAV- measures selected by both patients and physicians.**

**A deep neural network to serve as a fast and more accessible inflammatory SSC subset predictor, using the images of immunohistochemically-stained skin biopsies.**

**Possible SSC biomarkers for disease severity at the end-organ level.**

**Proposed marker to predict the rate of decline of lung function in SSC-ILD.**

**Serum interferon score may be a biomarker for active disease in patients with early dcSSc.**
Mert is a fellow in training at Istanbul University-Cerrahpasa. His main interests are autoinflammatory disorders and large vessel vasculitis. Mert is a member of the Peer Mentoring Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0190</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Miscellaneous Rheumatic &amp; Inflammatory Diseases Poster I</td>
<td>Kuemmerle-Deschner, J (Germany)</td>
<td>LONG-TERM SAFETY OF CANAKİNUMAB IN PATIENTS WITH AUTOINFLAMMATORY PERIODIC FEVER SYNDROMES – INTERIM ANALYSIS OF THE RELIANCE REGISTRY</td>
</tr>
<tr>
<td>Poster 1083</td>
<td>Monday 08.11.2021 08:30</td>
<td>Miscellaneous Rheumatic &amp; Inflammatory Diseases Poster II</td>
<td>Nazzar-Romero, S (USA)</td>
<td>OUTCOMES OF COVID-19 ILLNESS IN SYSTEMIC AUTOINFLAMMATORY DISEASES AND CHANGES IN FLARES DURING THE COVID-19 PANDEMIC: AN INTERNATIONAL SURVEY</td>
</tr>
<tr>
<td>Poster 1103</td>
<td>Monday 08.11.2021 08:30</td>
<td>Miscellaneous Rheumatic &amp; Inflammatory Diseases Poster II</td>
<td>Baker, M (USA)</td>
<td>DISEASE ASSOCIATIONS WITH VERY HIGH SERUM IGG4 CONCENTRATIONS: A RETROSPECTIVE MULTI-CENTER STUDY</td>
</tr>
<tr>
<td>Poster 1110</td>
<td>Monday 08.11.2021 08:30</td>
<td>Miscellaneous Rheumatic &amp; Inflammatory Diseases Poster II</td>
<td>Kul-Cinar, O (United Kingdom)</td>
<td>CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES: GOSH AND NATIONAL AMYLOIDOSIS CENTRE EXPERIENCE</td>
</tr>
<tr>
<td>Poster 1114</td>
<td>Monday 08.11.2021 08:30</td>
<td>Miscellaneous Rheumatic &amp; Inflammatory Diseases Poster II</td>
<td>Gilbert, E (USA)</td>
<td>PACHYMENİNGİTİS: THE MAYO CLİNİC EXPERIENCE</td>
</tr>
<tr>
<td>Oral 1426</td>
<td>Monday 08.11.2021 10:30</td>
<td>Plenary Session III</td>
<td>Ferrada, M (USA)</td>
<td>GENOTYPE AND TRANSFUSION DEPENDENCE PREDICTS MORTALITY IN VEXAS SYNDROME, A NEWLY DESCRIBED DISEASE WITH OVERLAP INFLAMMATORY AND HEMATOLOGIC FEATURES</td>
</tr>
<tr>
<td>Oral 1454</td>
<td>Monday 08.11.21 15:30</td>
<td>Miscellaneous Rheumatic &amp; Inflammatory Diseases: New Insights into Therapies &amp; Mechanisms of Disease</td>
<td>Klein, A (USA)</td>
<td>RHAPSODY: RILONACEPT, AN IL-1A AND IL-1B TRAP, RESOLVES PERICARDİTİS EPİSODES AND REDUCES RİSK OF RECURRENCE İN A PHASE 3 TRIAL OF PATİENTS WITH RECURRENT PERİCARDİTİS</td>
</tr>
</tbody>
</table>

The long-term efficacy and safety of canakinumab was investigated in both pediatric and adult autoinflammatory disorders.

The flare frequency and outcomes in patients with systemic autoinflammatory disorders were assessed during the COVID-19.

The association of very high serum IgG4 concentrations with a diagnosis of IgG4-RD was evaluated retrospectively.

A total of 48 CAPS patients were evaluated in terms of clinical presentations, genetic mutations and treatment responses.

Clinical presentation, demographics, imaging features, laboratory data, treatment, and outcome were evaluated in 153 patients.

Median survival and predictors of mortality in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome were evaluated.
**IMAGING**

Giacomo Cafaro

Giacomo is a consultant rheumatologist and PhD candidate at the Rheumatology Unit of the University of Perugia, Italy. His research interests are mainly focused on T cell biology and ultrasound in rheumatoid arthritis, Sjögren’s syndrome and psoriatic arthritis. Giacomo is a member of the Newsletter Sub-Committee.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Poster 0156</strong></td>
<td><strong>Saturday 06.11.2021 08:30</strong></td>
<td>Imaging of Rheumatic Diseases Poster</td>
<td>Sanchez Prado, E (Argentina)</td>
<td>TENOSYNOVITIS DETECTED BY POWER DOPPLER ULTRASOUND: A DIFFERENTIAL FEATURE OF PATIENTS WITH SERONEGATIVE RHEUMATOID ARTHRITIS</td>
</tr>
<tr>
<td><strong>Poster 0165</strong></td>
<td><strong>Saturday 06.11.2021 08:30</strong></td>
<td>Imaging of Rheumatic Diseases Poster</td>
<td>Prata, A (Portugal)</td>
<td>SHEAR-WAVE ELASTOGRAPHY EVALUATION OF MAJOR SALIVARY GLANDS AND CORRELATION WITH B-MODE FINDINGS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME</td>
</tr>
<tr>
<td><strong>Poster 0166</strong></td>
<td><strong>Saturday 06.11.2021 08:30</strong></td>
<td>Imaging of Rheumatic Diseases Poster</td>
<td>Maruseac, M (Belgium)</td>
<td>DIGITAL EXTENSOR PARATENONITIS IS FREQUENT IN EARLY RHEUMATOID ARTHRITIS</td>
</tr>
<tr>
<td><strong>Poster 0169</strong></td>
<td><strong>Saturday 06.11.2021 08:30</strong></td>
<td>Imaging of Rheumatic Diseases Poster</td>
<td>Taniguchi, Y (Japan)</td>
<td>ULTRASONOGRAPHY OF AURICULAR CARTILAGE IS A USEFUL TOOL FOR DIAGNOSING AND MONITORING DISEASE ACTIVITY IN RELAPSING POLYCHONDritis</td>
</tr>
<tr>
<td><strong>Oral 0468</strong></td>
<td><strong>Saturday 06.11.2021 11:00</strong></td>
<td>Imaging of Rheumatic Diseases</td>
<td>van Dijk, B (Netherland s)</td>
<td>DURING DEVELOPMENT OF RHEUMATOID ARTHRITIS, INTERMETATARSAL BURSITIS MAY OCCUR BEFORE CLINICAL JOINT SWELLING: A LARGE MRI STUDY IN PATIENTS WITH CLINICALLY SUSPECT ARTHRALTIA</td>
</tr>
<tr>
<td><strong>Poster 0901</strong></td>
<td><strong>Sunday 07.11.2021 8:30</strong></td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes Poster II</td>
<td>Chan, J (Canada)</td>
<td>LOW DOSE DUAL ENERGY CT SCAN FOR THE DETECTION OF BONE MARROW EDEMA AND EROSIONS IN AXIAL SPONDYLOARTHRITIS</td>
</tr>
<tr>
<td><strong>Poster 0905</strong></td>
<td><strong>Sunday 07.11.2021 8:30</strong></td>
<td>Spondyloarthritis Including PsA – Diagnosis, Manifestations, &amp; Outcomes Poster II</td>
<td>Poddubnyy, D (Germany)</td>
<td>ARTIFICIAL NEURAL NETWORK FOR THE RECOGNITION OF ACTIVE INFLAMMATORY CHANGES COMPATIBLE WITH AxSpA ON MAGNETIC RESONANCE IMAGING OF SACROILIAC JOINTS</td>
</tr>
</tbody>
</table>

*The identification of differences between rheumatoid and seronegative arthritis may help to improve diagnosis and classification.*

Shear-wave elastography is accurate in differentiating healthy from Sjögren syndrome salivary glands and may serve as a useful additional tool.

*Description of high prevalence of paratenonitis in early RA, usually considered a feature of PsA.*

**US of auricular cartilage is very helpful in distinguishing RP, trauma and cellulitis.**

Intermetatarsal bursitis may precede the clinical manifestations of RA in a significant proportion of patients.

Low dose DECT is very specific in identifying sacroiliitis and may change the diagnostic paradigm of axSpA.

Artificial Neural Network accurately detects sacroiliitis and may help to overcome limits due to imaging interpretation.
Selcan has finished her pediatric rheumatology fellowship and MSc on Pediatric Autoinflammatory Diseases at Hacettepe University, Turkey. Currently, she is working as a pediatric rheumatologist at Erzurum Research and Training Hospital. She is a member of EMERGE and her major interests include juvenile SLE, APS and childhood vasculitis.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0245</td>
<td>Saturday, 06.11.2021 8:30</td>
<td>Pediatric Rheumatology – Clinical Poster I</td>
<td>Brunner, H (USA)</td>
<td>LONG-TERM SAFETY AND EFFECTIVENESS OF ABATACEPT TREATMENT IN PATIENTS WITH JIA: 5-YEAR RESULTS FROM THE PRCSG/PRINTO JIA REAL-WORLD REGISTRY</td>
</tr>
<tr>
<td>Poster 0764</td>
<td>Sunday, 07.11.2021 8:30</td>
<td>Pediatric Rheumatology – Clinical Poster II</td>
<td>Foeldvari, I (USA)</td>
<td>PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS HAVE A DISTINCT PATTERN OF ORGAN INVOLVEMENT: RESULTS FROM THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT</td>
</tr>
<tr>
<td>Oral 0975</td>
<td>Sunday, 07.11.2021 14:15</td>
<td>Pediatric Rheumatology – Clinical</td>
<td>Weiss, P (USA)</td>
<td>DATA-DRIVEN MRI DEFINITIONS FOR ACTIVE AND STRUCTURAL SACROILIAC JOINT LESIONS IN JUVENILE SPONDYLOARTHITIS TYPICAL OF AXIAL DISEASE</td>
</tr>
<tr>
<td>Oral 0978</td>
<td>Sunday, 07.11.2021 15:00</td>
<td>Pediatric Rheumatology – Clinical</td>
<td>Khojah, A (USA)</td>
<td>IMMUNOLOGICAL AND CLINICAL FEATURES OF UNTREATED JUVENILE DERMATOMYOSITIS PATIENTS WITH ELEVATED NEOPTERIN</td>
</tr>
<tr>
<td>Poster 1013</td>
<td>Monday, 08.11.2021 08:30</td>
<td>Pediatric Rheumatology – Basic Science Poster</td>
<td>Webb, K (South Africa)</td>
<td>SARS-COV-2 ANTIBODY PHENOTYPE AND IMMUNE GENE EXPRESSION IN MULTI-SYSTEM INFLAMMATORY SYNDROME IN CHILDREN</td>
</tr>
<tr>
<td>Poster 1618</td>
<td>Tuesday 09.11.2021 08:30</td>
<td>Pediatric Rheumatology – Clinical Poster III</td>
<td>Gedik, KC (USA)</td>
<td>DISEASE FLARES IN CANDLE/PRAAS WITH DOSE REDUCTIONS OF BARICITINIB</td>
</tr>
<tr>
<td>Oral 1928</td>
<td>Tuesday 09.11.21 15:45</td>
<td>Pediatric Rheumatology – Basic Science</td>
<td>Cron, R (USA)</td>
<td>IN VITRO AND IN VIVO EVIDENCE FOR DOCK8 AS A RISK ALLELE FOR CYTOKINE STORM SYNDROME, INCLUDING COVID-19 AND MIS-C</td>
</tr>
</tbody>
</table>

DOCK8 mutations may be a risk factor for Cytokine Storm Syndrome development which is a fatal condition.
Thomas is a physiotherapist for patients with osteoarthritis and inflammatory arthritis. He obtained a PhD in epidemiology at the Sorbonne University in Paris, France. He is studying the determinants of physical activity in patients with inflammatory arthritis. He is currently undertaking a postdoc at the Centre for Epidemiology in Manchester, UK. Thomas is a member of the EULAR Knowledge Transfer Subcommittee.

### HPR section

**Thomas Davergne**

The link between foot disorders and increased mortality highlights the importance of foot management.

**Poster 0804**

**Sunday, 07.11.21**

**08.30**

**RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA**

**Tsang, C, China**

**VALIDATION OF THE 2010 ACR/EULAR CLASSIFICATION CRITERIA OF RHEUMATOID ARTHRITIS (RA) IN A NURSING-LED TRIAGE**

This work reinforces the cultural validation of the ACR/EULAR 2010 classification criteria, in Chinese RA patients in a nurse-led triage clinic.

**Poster 0815**

**Sunday, 07.11.21**

**08.30**

**RA – Treatments Poster I: Comparative Effectiveness, Biosimilars, Withdrawal, & the Real World**

**Solomon, D, Canada**

**IMPLEMENTING TREAT TO TARGET (TTT) FOR RHEUMATOID ARTHRITIS (RA) THROUGH A VIRTUAL LEARNING COLLABORATIVE (LC) PROGRAM DURING COVID**

Implementation of TTT for RA can be improved through a relatively low-cost virtual Learning collaborative.

**Poster 0804**

**Sunday, 07.11.21**

**08.30**

**RA – Diagnosis, Manifestations, & Outcomes Poster II: Miscellaneous Aspects of RA**

**Tsang, C, China**

**VALIDATION OF THE 2010 ACR/EULAR CLASSIFICATION CRITERIA OF RHEUMATOID ARTHRITIS (RA) IN A NURSING-LED TRIAGE**

This work is interesting because it reinforces the cultural validation of the ACR/EULAR 2010 classification criteria, here in Chinese RA patients in a nurse-led triage clinic.

**Poster 0664**

**Sunday, 07.11.21**

**08.30**

**Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I**

**Stawart, S, New Zealand**

**WHICH ATTRIBUTES ARE THE MOST AND LEAST IMPORTANT TO PATIENTS WHEN CONSIDERING GOUT FLARE BURDEN OVER TIME? A BEST-WORST SCALING CHOICE STUDY**

This survey provides insight into the fact that for patients suffering from gout flares, important burden comes from the worst episode of gout flare rather than the accumulation of all flares over time, which appears to be relatively less.
Féline Kroon

Féline is a rheumatologist-in-training at Zuyderland Medical Center in Heerlen (The Netherlands). She did her PhD on treatment and outcome measurement in hand osteoarthritis at the Leiden University Medical Center. She is a member of the OMERACT Technical Advisory Group, and currently also fellow in EULAR recommendations task force. Féline is a member of the Newsletter Sub-Committee and EMEUNET Country Liaison for The Netherlands.

<table>
<thead>
<tr>
<th>Type, n°</th>
<th>Date, time</th>
<th>Session</th>
<th>Author</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 0085</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Epidemiology &amp; Public Health Poster I: COVID-19 &amp; Vaccination</td>
<td>Patel, N (USA)</td>
<td>ASSOCIATION OF CD20 INHIBITOR USE WITH SEVERE COVID-19 OUTCOMES</td>
</tr>
<tr>
<td>Poster 0086</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Epidemiology &amp; Public Health Poster I: COVID-19 &amp; Vaccination</td>
<td>Conway, R (Ireland)</td>
<td>SARS-COV-2 INFECTION AND COVID-19 OUTCOMES IN RHEUMATIC DISEASE: A SYSTEMATIC LITERATURE REVIEW</td>
</tr>
<tr>
<td>Poster 0097</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Epidemiology &amp; Public Health Poster I: COVID-19 &amp; Vaccination</td>
<td>Hasseli, R (Germany)</td>
<td>OUTCOME OF SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDER TREATMENT WITH JANUS KINASE INHIBITORS COMPARED TO TUMOUR NECROSIS FACTOR INHIBITORS</td>
</tr>
<tr>
<td>Poster 0102</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Epidemiology &amp; Public Health Poster I: COVID-19 &amp; Vaccination</td>
<td>Regierer, A (Germany)</td>
<td>DIFFERENTIAL IMPACT OF TNFI, JAKI AND RITUXIMAB ON THE OUTCOME OF SARS-COV-2 INFECTION IN RMD PATIENTS</td>
</tr>
<tr>
<td>Poster 0108</td>
<td>Saturday 06.11.2021 08:30</td>
<td>Epidemiology &amp; Public Health Poster I: COVID-19 &amp; Vaccination</td>
<td>Sood, A (USA)</td>
<td>EFFICACY OF SARS-COV-2 VACCINE IN PATIENTS WITH RHEUMATIC DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
</tr>
<tr>
<td>Oral 1421</td>
<td>Monday 08.11.2021 09:15</td>
<td>SLE – Diagnosis, Manifestations, &amp; Outcomes I: COVID-19 Vaccine Experience &amp; Translational Science</td>
<td>Felten, R (France)</td>
<td>EFFICACY AND TOLERANCE OF VACCINATION AGAINST COVID-19 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE INTERNATIONAL VACOLUP STUDY</td>
</tr>
<tr>
<td>Oral 1445</td>
<td>Monday 08.11.2021 14:45</td>
<td>RA – Treatments II: New Findings in Established Therapies</td>
<td>Singh, N (USA)</td>
<td>ASSOCIATION BETWEEN BASELINE USE OF RITUXIMAB AND COVID-19 OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA)</td>
</tr>
</tbody>
</table>

Large matched cohort study assessing COVID-19 outcomes in CD10 inhibitor users versus general population.

Overview of available literature (until February) on COVID-19 in patients with RMDs.

Association of treatment with JAKi vs. TNFi with prognosis of COVID-19 in RA, with attention for important confounding factors.

Large comparison of association of different RMD treatments on the prognosis of COVID-19.

Overview of studies on efficacy of vaccination against SARS-CoV-2 in patients with rheumatic diseases.

Large study of efficacy and safety of vaccination against SARS-CoV-2 in SLE patients, including risk of flare.
Register NOW for the Virtual Networking Event @ #ACR2021

Test your knowledge and lead your team to victory in **emeunet Trivia Game**

on Wednesday evening (**November 10th 2021**) 7.00 pm CET on Microsoft Teams

Win EULAR Learning Material!

Limited space, please register as soon as possible!

Register [HERE](#)

More details will be provided following registration

---

**SAVE THE DATE!**

November 10th 2021
EULAR continues to provide valuable content and guidance for clinicians and patients with Rheumatic Musculoskeletal Diseases (RMDs) around the world during the COVID-19 pandemic.

Access the **EULAR COVID-19 Repository for clinicians** - a dedicated space for clinicians and patients where all COVID-related resources and guidelines are concentrated.

- **EULAR guidelines:**
  - COVID-19 Clinic visit guidelines
  - EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2
  - Factors associated with COVID-19-related death in people with rheumatic diseases
  - Plain Language Summaries of the COVID-19 Global Rheumatology Alliance
  - **EULAR - COVID-19 Reporting database for rheumatologists and other clinicians.**
    - The EULAR - COVID-19 Database is a European pediatric and adult database to report on outcomes of COVID-19 in patients with RMDs. It has been updated with Module 2 – reports on cases of vaccination against SARS-CoV-2 of patients with RMDs are now being collected. The page also contains national registries.

- Information on vaccination against SARS-CoV-2 in patients with RMDs:
  - EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs by Prof. Johannes Bijlsma.
  - EULAR PARE Webinar on COVID-19 and vaccination in RMD patients: What we know so far

The EULAR viewpoint “**EULAR COVID-19 registry: lessons learnt and future considerations**” was published in the Annals of Rheumatic Diseases. The authors discuss what can be learnt from the ongoing pandemic in the context of rheumatology and what can be improved to be prepared to care for the patients under similar circumstances in the future.
UPCOMING EDUCATIONAL EVENTS

NOVEMBER 2021

ACR Convergence 2021
• When and Where: 05 – 09 Nov 2021, Virtual Event
• Website: https://www.rheumatology.org/Annual-Meeting

The Royal Society of Medicine: Vasculitis: From cell to service
• When and Where: 17 – 18 Nov 2021, Virtual Event
• Website: https://www.rsm.ac.uk/events/nephrology/2021-22/neq51/

VIB Translational Immunology Meeting
• When and Where: 22 – 23 Nov 2021, Ghent, Belgium
• Website: https://www.vibconferences.be/events/translational-immunology

7th Qatar Musculoskeletal Ultrasound Course - Level: Basic and Intermediate
• When and Where: 25 – 27 Nov 2021, Hybrid Event (Doha, Qatar + Online)
• Website: https://www.hamad.qa/EN/All-Events/7Qmusc/Pages/default.aspx

British Society for Immunology Annual Congress
• When and Where: 28 Nov – 1 Dec 2021, Hybrid Event (Edinburgh, UK + Online)
• Website: https://www.bsicongress.com

DECEMBER 2021

PRINTO Egypt Pediatric and Adolescent Rheumatology Conference
• When and Where: 01 – 03 Dec 2021, Cairo, Egypt
• Website: http://www.printoegypt.org/index.html

Central European Congress of Rheumatology
• When and Where: 02 – 04 Dec 2021, Bratislava, Slovakia
• Website: http://cecr2020.sk/

7th International Musculoskeletal UltraSound Course
• When and Where: 09 – 11 Dec 2021, Athens, Greece
• Website: https://event.concopco.com/cms/mitoscourse2021
EULAR ONLINE COURSES AND MODULES

Compilation of EULAR Online Modules
EULAR has developed e-learning opportunities with the newest updates in the field of rheumatology. 99 modules are available, covering different areas of rheumatology

- **Fee**: 25 EUR for each module
- **Start**: no deadline / any time
- **Available for**: 1 year after booking

10th EULAR Online Introductory Ultrasound Course
The course, covering 7 modules, is designed for approx. 7 months of training, the expected learning time per week is around 2 1/2 hours. Upon passing the examination, a EULAR certificate will be issued.

- **Fee**: 150 EUR
- **Start**: 14.10.2021; **Registration deadline**: 30.11.2021
- **Available for**: 1 year + 1 year extension

10th EULAR Online Course on Systemic Sclerosis
The Course consists of 10 modules dealing with physiopathology, clinical aspects and management of SS. All modules are developed by EUSTAR

- **Fee**: 150 EUR
- **Start**: 14.10.2021; **Registration deadline**: 30.11.2021
- **Available for**: 1 year + 1 year extension

16th EULAR Online Course on Rheumatic Diseases
The course is managed by a scientific course committee controlling the structure and content of the course and performing regular quality control and advancement. The full version covers the entire field of rheumatology and consists of 55 illustrated modules (of which some are optional), each one covering a specific topic. Each module corresponds to approximately 5 - 8 hours of study for the student, totalling around 275 - 440 hours of educational training. Knowledge and skills are targeted to suit a level of knowledge appropriate for the final years of training as a rheumatologist. It will finish with an online examination and upon passing, with a EULAR Certificate.

- **Fee**: 150 EUR
- **Start**: 14.10.2021; **Registration deadline**: 30.11.2021
- **Available for**: 2 years + 1 year extension
13th EULAR Online Course on Connective Tissue Diseases
The Course consists of 16 modules which deal with immunology and systemic auto-immune diseases, such as SLE, scleroderma, and vasculitis.
- **Fee:** 150 EUR
- **Start:** 14.10.2021; **Registration deadline:** 30.11.2021
- **Available for:** 1 year + 1 year extension

1st EULAR Online Course on Patient Education for Physicians and Health Professionals
The Course consists of 4 modules (approx. 6 hours each). The learning objectives are: understand the problematics of chronic rheumatic diseases, understand issues of patient education, develop attitudes in the relationship with the patient, elaborate a program of patient education, perform an educational diagnosis, design and animate educational workshops evaluate a program and among different learning objectives. Upon passing the examination a EULAR certificate will be issued.
- **Fee:** 150 EUR
- **Start:** 14.10.2021; **Registration deadline:** 30.11.2021
- **Available for:** 1 year + 1 year extension

3rd EULAR Online Course for Systemic Lupus Erythematosus
The Course consists of 12 modules covering the recent updates in in diagnosing and managing SLE, as well as the recent updates to management guidelines.
- **Fee:** 150 EUR
- **Start:** 14.10.2021; **Registration deadline:** 30.11.2021
- **Available for:** 1 year + 1 year extension

4th EULAR Online Course on Imaging in RMDs
The Course covers 3 modules. The learner level is aimed primarily at Section Residents and Fellows in Training as well as Rheumatologists. It aims to educate rheumatologists and future rheumatologists on how to interpret imaging examinations in chronic inflammatory RMDs and to use the imaging results to guide their daily treatment.
- **Fee:** 150 EUR
- **Start:** 14.10.2021; **Registration deadline:** 30.11.2021
- **Available for:** 1 year + 1 year extension
7th EULAR Online Course for Health Professionals in Rheumatology
The course consists of a total of 8 modules. Care is given to integrate the multidisciplinary perspective of the treatment of rheumatic diseases.
- **Fee**: 150 EUR
- **Start**: 14.10.2021; **Registration deadline**: 30.11.2021
- **Available for**: 1 year + 1 year extension

8th EULAR/PRES Online Course in Paediatric Rheumatology
The 11-module course represents a joint effort of EULAR and the Paediatric Rheumatology European Society (PRES), offering a deep insight of all the aspects related to rheumatic diseases in children and adolescents including their impact on the growing body and the differential diagnosis with other paediatric disorders.
- **Fee**: 150 EUR
- **Start**: 14.10.2021; **Registration deadline**: 30.11.2021
- **Available for**: 1 year + 1 year extension
By 2023, EULAR will be the leading provider of education in rheumatic and musculoskeletal diseases (RMDs).

EULAR School of Rheumatology

- **EULAR Online courses:**  
  RMD: EULAR Course on Rheumatic Diseases  
  US: EULAR Online Introductory Ultrasound Course  
  IMG: EULAR Online Course on Imaging in RMDs  
  PAED: EULAR / PRES Online Course in Paediatric Rheumatology  
  HPR: EULAR Online Course for Health Professionals in Rheumatology  
  SSc: EULAR Online Course on Systemic Sclerosis

- **The EULAR Educational Cooperation with National Societies (EULAR ECONS)**

- **5th EULAR Immunology Course** 18.03 –19.03.2022
The EULAR Research Consultation Service

Get free advice on your research from experienced scientists

How does it work?

1. Select your support area and describe your needs in a short online form
2. Get matched with an experienced scientist
3. Obtain up to 10 hours of free consultation
4. Share your feedback upon service completion

Support Areas

- Basic/Translational Research (using patient/human materials, e.g. cells, serum... or Dedicated animal models of RMDs to address bedside-to-bench research questions)
- Clinical Research
- Epidemiology and Public Health
- Health Services Research
- Implementation Science

Study design
Statistical methods
Sampling strategy
Data collection and analysis
Patient involvement
Participant recruitment strategy
Access to patient and human materials
Access to equipment and technologies
Research reporting
EU grant writing support

The EULAR Research Consultation Service is offered through the EULAR Research Centre. The service is available for researchers based in EULAR-affiliated countries.
The EULAR Outcome Measures Library (OML) aims to be a comprehensive database of validated instruments (indices, questionnaires, scales, or others), with an emphasis on patient-reported outcomes (PRO) used in rheumatology. The EULAR OML was created by rheumatologists, health professionals, students and patients, all of whom are engaged in the field of rheumatology. The database includes a detailed description of each instrument, including the instrument itself (and validated language versions, if available), useful references, a description of the population(s)/setting(s) where it has been validated, recommendations and rules for use, guideline for interpretation of the results in clinical practice or in research, information on the most relevant psychometric properties of each instrument. Instruments are categorized by disease or by topic. Also, guidelines for interpretation of results in both practice and research settings are provided. The OML is an ongoing project and is frequently updated with the most recent information on PROs in rheumatology.

For more information visit:

http://oml.eular.org/
EMEUNET PODCASTS!

Are you too busy to read the whole Newsletter? Do you want to keep updated about the main EMEUNET activities and save time?

With our Podcasts, you can get updated while on the go, with extracts of the recent newsletters, highlights of the most recent publications in the field of Rheumatology, selected for you by EMEUNET members (What Is New), interviews and review of other EMEUNET activities.

Where to listen:

SHARE YOUR IDEAS!

Over the years EMEUNET has developed several projects covering different topics and areas of interest. However, we always appreciate any suggestions and welcome new ideas to expand on what we currently offer to EMEUNET members. Make your voice heard and share your ideas with us!

For additional suggestions and ideas, just write down some lines to summarize your proposal and send it either via email at emeunet@eular.ch or through our website (http://emeunet.eular.org/contact_us.cfm). Don't forget to provide your contacts so we can come back to you for additional details!

More information about EMEUNET can be found at http://emeunet.eular.org

www.facebook.com/EMEUNET
www.twitter.com/EMEUNET
https://www.linkedin.com
EMEUNET Tube
EMEUNET Podcast